Avalon GloboCare enters $3.5M ATM offering, reports Lab Services MSO financials

Avalon GloboCare Corp.

Entered ATM sales agreement with Roth Capital for up to $3.5M of common stock; 3% commission.
Owns 40% of Lab Services MSO (Costa Mesa, CA); 2022 revenue $14.7M, net income $6.3M.
Suspended cellular therapy R&D to focus on laboratory rollup and KetoAir commercialization.
KetoAir breathalyzer (FDA Class I) detects acetone; exclusive distribution rights in NA, SA, EU, UK.
Lab Services MSO completed over 600,000 tests since inception; state-of-the-art facility.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Avalon GloboCare Corp. entered into Sales Agreement with Roth Capital Partners, LLC valued at up to $3,500,000 (effective 2023-06-16).

Action: entry
Agreement: atm program
Counterparty: Roth Capital Partners, LLC
Value: up to $3,500,000
Effective: 2023-06-16

Exact text from the filing

On June 16, 2023, Avalon GloboCare Corp. (the “Company”) entered into that certain sales agreement (the “Sales Agreement”) with Roth Capital Partners, LLC (“Roth”), as sales agent, pursuant to which the Company may issue and sell, from time to time, through Roth, shares of its common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

276 material agreements filed in the last 30 days. Browse all material agreements →

Avalon GloboCare Corp. filing history →

Source: SEC EDGAR

accession 0001213900-23-049645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.